Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)"

Affiliations

¹ Departments of Vascular Medicine (D.M.K., M.J.A.M.B., J.J.P.K.).
² Pediatrics (D.M.K., M.J.A.M.B., A.W.).
³ Lipid Clinic, Medical Department, Oslo University Hospital, Norway (G.C.).
⁴ Department of Pediatrics, University of Toronto, Labatt Family Health Center, The Hospital for Sick Children, Canada (B.W.C.).
⁵ Department of Hepatology and Metabolic Center, University Hospitals Leuven, Belgium (D.C.).
⁶ Healthy Heart Program Prevention Clinic, St. Paul's Hospital, Vancouver, Canada (G.A.F.).
⁷ Department of Medicine, University of British Columbia, Vancouver, Canada (G.A.F.).
⁸ Clinique des Maladies Lipidiques de Québec Inc, Canada (C.G.).
⁹ Department of Medicine, Université de Montréal, Canada (D.G.).
¹⁰ Department of Pediatrics, McMaster University, Hamilton, Canada (K.M.M.).
¹¹ Metabolic & Atherosclerosis Research Center, Cincinnati, OH (T.T., E.A.S.).
¹² AstraZeneca Pharmaceuticals LP, Wilmington, DE (E.M., J.R.).
¹³ AstraZeneca, Macclesfield, UK (P.D.M.).
¹⁴ Clinical Epidemiology, Biostatistics and Bioinformatics (B.A.H.), Academic Medical Center, Amsterdam, the Netherlands.

Comment

D Meeike Kusters et al. Circulation. 2018.

. 2018 Feb 6;137(6):641-642.

doi: 10.1161/CIRCULATIONAHA.117.031676.

¹ Departments of Vascular Medicine (D.M.K., M.J.A.M.B., J.J.P.K.).
² Pediatrics (D.M.K., M.J.A.M.B., A.W.).
³ Lipid Clinic, Medical Department, Oslo University Hospital, Norway (G.C.).
⁴ Department of Pediatrics, University of Toronto, Labatt Family Health Center, The Hospital for Sick Children, Canada (B.W.C.).
⁵ Department of Hepatology and Metabolic Center, University Hospitals Leuven, Belgium (D.C.).
⁶ Healthy Heart Program Prevention Clinic, St. Paul's Hospital, Vancouver, Canada (G.A.F.).
⁷ Department of Medicine, University of British Columbia, Vancouver, Canada (G.A.F.).
⁸ Clinique des Maladies Lipidiques de Québec Inc, Canada (C.G.).
⁹ Department of Medicine, Université de Montréal, Canada (D.G.).
¹⁰ Department of Pediatrics, McMaster University, Hamilton, Canada (K.M.M.).
¹¹ Metabolic & Atherosclerosis Research Center, Cincinnati, OH (T.T., E.A.S.).
¹² AstraZeneca Pharmaceuticals LP, Wilmington, DE (E.M., J.R.).
¹³ AstraZeneca, Macclesfield, UK (P.D.M.).
¹⁴ Clinical Epidemiology, Biostatistics and Bioinformatics (B.A.H.), Academic Medical Center, Amsterdam, the Netherlands.

No abstract available

Comment on

Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Braamskamp MJAM, et al. Circulation. 2017 Jul 25;136(4):359-366. doi: 10.1161/CIRCULATIONAHA.116.025158. Epub 2017 Jun 7. Circulation. 2017. PMID: 28592434
Letter by Koh Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)".
Koh KK. Koh KK. Circulation. 2018 Feb 6;137(6):639-640. doi: 10.1161/CIRCULATIONAHA.117.030934. Circulation. 2018. PMID: 29431666 No abstract available.